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ABSTRACT
Background: Breast cancer is the most common invasive cancer in females but often has more favourable 
tumour biology in the older age group. More than 30% of those diagnosed with breast cancer worldwide are 
aged ≥ 65. Some report this percentage to be even higher, reaching up to more than 50% in developed 
countries that have a longer overall life expectancy. 
Within this group, hormone receptor-positive and human epidermal growth factor-2 (HER-2) negative are the most fa-
vourable tumour biological patterns. In contrast, the triple-negative breast cancer group has the worst prognosis.
Invasive breast cancers in younger age groups have a more poorly differentiated histological grade, more hormone 
receptor-negative status, a remarkable extent of lympho-vascular invasion and a greater expression/amplification of 
HER-2 than older age groups. HER-2 receptor is amplified and over-expressed in about 20–30% of invasive 
breast cancers within all age groups.
To analyse the status of HER-2 receptors early invasive breast cancer in relation to the histological subtype in 
the older age group.
Methods: The study group includes 150 patients with early breast cancer . The patho-morphological data and 
immune-histochemistry results of invasive cancer have been analysed, this included histology subtype, 
grade, oestrogen/progesterone receptor status as well as HER-2 expression. 
Results: HER-2 expression was only seen in 17% of cases, it was seen mainly in Grade 3 cancers (9%), followed 
by Grade 2 (6%), with Grade 1 cancer accounting for only 1% of the study group.
Conclusions: Patients with breast cancer aged ≥ 70 are seen to have less aggressive biology and expression 
of HER-2 receptors.
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Introduction
Breast cancer is the most common cancer among 
females, accounting for one-third of female cancers, 
and is the second leading cancerous cause of death 
in women after lung cancer [1]. The risk of developing 
breast cancer in a woman aged ≥ 70 is much higher 
than in women aged below 70 years.
The estimated risk reaches 3.82% (1 in 26 women) 
at the age of 70, almost more than twice the risk of 
a 40-year old woman (1.47% or 1 in 62 women) [2].
HER-2 is a  receptor for epidermal growth factor 
which stimulates different intracellular signal transduc-
tion pathways related to cell growth and differentiation 
control. HER-2 overexpression is detected in 20–30% of 
diagnosed invasive breast cancers and this is associat-
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ed with aggressive tumour features, poor prognosis and 
an unfavourable outcome [3]. The aim of this paper is 
to analyse the status of HER-2 receptors early invasive 
breast cancer in relation to the histological subtype in 
the older age group.
Methods
Patients
A  database of 150 patients aged ≥ 70 with early 
operable primary breast cancer has been analysed. The 
preoperative diagnosis was through triple assessment, 
including mammogram (Fig. 1) and histopathology. 
These patients had been managed at Basildon Uni-
versity Hospital (Essex-England) and Greater Poland 
Oncology Centre (Poznan, Poland). The treatment 
period was from 2011 to 2016. The patient information 
has been identified from the electronic records including 
demographic, clinical and histopathological details.
Immuno-histochemical analysis
The immuno-histochemical studies were performed 
by the local team in each hospital using local diag-
nostic techniques. Quick score (Q-Score) technique 
was used at Basildon University Hospital to examine 
oestrogen and progesterone receptor status. The final 
scores ranged between 0–8, where 0 was negative and 
8 strongly positive. At the Poznan centre, oestrogen 
and progesterone receptor status was performed us-
ing immune-histochemistry on the core biopsy. If the 
histochemical score (H score) was 50% or more, the 
outcome was a positive result.
Figure 1. A — Mammogram — CC view; B — Mammogram — MLO view; Right mammogram — Spiculated mass lesion 
right UOQ measuring approximately 31 × 20 × 19 mm. Appearances are highly suspicious for malignancy. Prominent 
lymph nodes seen in the axilla, suspicious of metastatic disease
A B
Figure 2. HER-2 negative invasive breast cancer
The technique to measure HER-2 protein uses an 
antibody which probes for HER-2 in tumour cells. Score 
(0) or (1+) were reported as negative (Fig. 2) and (3+) 
as positive [Figure 3]. The result was reported as bor-
derline if the score was (2+). FISH test (Fluorescence 
In-Situ Hybridization) was used to measure HER-2 gene 
amplification in the tumour cells of borderline cas-
es. When FISH score was ≥ 2, the result was regarded 
as positive.
Results
The group was composed of 150 patients with an 
age range of 70–88 and a median age of 76. Grade 
2 cancer was the most common among this group 
(53% of cases), followed by Grade 3 (23%) and Grade 
1 (21%) (Tab. 1). HER-2 expression was only seen in 
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Figure 3. HER-2 positive invasive breast cancer
Table 1. HER-2 status in 150 breast cancer patients aged ≥ 70, operated on for early breast cancer
Age Grade I Grade II Grade III Total
HER2 — Negative
70 –74 9 (6%) 25 (17%) 7 (5%) 41 (27%)
75 –79 12 (8%) 24 (16%) 8 (5%) 44 (29%)
80 > 9 (6%) 21 (14%) 10 (6%) 40 (26%)
HER2 — Positive
70 –74 2 (1%) 5 (3%) 6 (4%) 13 (9%)
75 –79 0 3 (2%) 4 (3%) 7 (5%)
80 > 0 2 (1%) 3 (2%) 5 (3%)
Total 32 (21%) 80 (53%) 38 (25%) 150 (100%)
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Figure 4. HER-2 status distribution pattern status in 
150 breast cancer patients aged ≥ 70, operated on for 
early breast cancer
17% of cases (n = 25) (Fig. 4). HER-2 positive was seen 
mainly in Grade 3 cancers (9%), followed by Grade 
2 (6%), with Grade 1 cancer accounting for only 1% 
of the study group (Fig. 5). Triple negative cancer was 
detected in just 10% (Tab. 1, Fig. 6).
Discussion
HER-2 is a cell membrane protein receptor mediated 
by the transmission of signals controlling normal cell 
growth and differentiation. In general, the number of 
existing HER-2 cell membrane receptors in normal cells 
is small (Fig. 7). When the number of HER-2 receptors 
is high, the cell signalling is stronger (Fig. 8), leading to 
amplified responsiveness to epidermal growth factors 
and carcinogenesis [4].
It has been reported that the incidence of breast 
carcinoma increases with age, with approximately 
30% of new breast carcinoma cases being diagnosed 
in patients ≥ 70 [5]. Breast cancer in advanced age 
has different biological features and clinical behaviour. 
For example, elderly breast cancer often expresses 
remarkable positivity for oestrogen receptor (ER), 
lower histopathological grade, and HER-2 negative 
tumours [6–10]. The younger age groups tend to 
have a more poorly differentiated histological grade, 
more hormone receptor negative status, a remarkable 
extent of lympho-vascular invasion and greater expres-
sion/amplification of HER-2. However, there is also data 
which reports that breast cancer is more aggressive in 
the elderly. 
In 2008, Durbecq et al analysed the effect of ageing 
on the incidence of breast cancer molecular subtypes in 
2723 breast cancer cases. The results showed almost 
19% of older women had luminal B tumours. This group 
is more likely to present with a higher histopathological 
grade, larger tumour size, and increased predisposition 
to lymph node metastasis, despite being hormone 
receptor positive [11]. Recent studies indicate that 
the percentage of HER-2 positive cases amongst the 
older age group with breast cancer accounted for 10% 
to 20%, which is similar to the figures reported in the 
entire breast cancer population [12]. The data also 
suggests that tumour specific features should be used 
to assess the risk of relapse and to plan management. 
The age progression itself is associated with changes 
in biological breast structure and physiology, such as 
increased sensitivity to oestrogen hormone, epithelial 
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Figure 5. HER-2 receptor status in different tumour grades in 150 breast cancer patients aged ≥ 70, operated on for 
early breast cancer
Figure 6. Receptor status in 150 breast cancer patients aged ≥ 70, operated on for early breast cancer; ER — Oestrogen 
Receptor; PR — Progesterone Receptor; HER2 — Human Epidermal Growth Factor-2 Receptor
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Figure 7. The normal number of Human Epidermal Growth 
Factor-2 Receptor (HER-2) in the cell
Figure 8. Over expression rate of Human Epidermal Growth 
Factor-2 Receptor (HER-2)
Figure 9. The monoclonal antibody Trastuzumab acting 
by blocking HER-2 receptors
cell alterations, immune senescence, and tumour mi-
croenvironment modifications. All of these factors could 
be related to an increased incidence of breast cancer 
and associated mortality [13].
A  positive aspect of the disease is that many di-
agnosed breast cancer cases are at an early stage 
(non-metastatic), and can be classified as a potentially 
curable disease. Since the 1990s, the monoclonal an-
tibody trastuzumab has greatly changed the treatment 
pattern and prognosis of human epidermal growth 
factor receptor-2 (HER-2) positive breast cancer. The 
trastuzumab attaches to the HER-2 receptor and pre-
vents the human epidermal growth factor from attaching 
to the same site. This prevents cell proliferation and 
initiates tumour cell death (Fig. 9). Many HER-2 pos-
itive breast cancer patients have a good response to 
trastuzumab-based systemic therapy. This has been 
reported in long-term follow-up observations, where 
the overall survival in this patient group has improved 
by 37% [14–18]. 
When breast cancer systemic therapy was intro-
duced, it did not have the same impact on the older 
age group as in younger age groups [12, 19–20]. 
The reason for this may have been that systemic 
therapy was less frequently given to the older age 
group, as the breast cancer was often less aggres-
sive and showed positive expression for oestrogen 
hormone receptor and negative expression for hu-
man epidermal growth factor receptor-2 (HER-2). 
There were also concerns about toxicity related to 
adjuvant chemotherapy and trastuzumab use [21]. 
However, it is now agreed that age should not be the 
main driver in decision making for cancer therapy in 
the older age group; this is based on recent reports 
and observations [14, 22]. A holistic assessment for 
individual patient physiological reserve and quality of 
life following the intervention are needed to offer the 
most appropriate management option.
The mortality associated with older age group 
breast cancer can be explained by under-treatment, 
late diagnosis, and insufficient individual screening. Fit 
elderly breast cancer patients should be given a fair 
chance and offered treatment in the same way as their 
younger counterparts.
Conclusion
In conclusion, patients with breast cancer 
aged ≥ 70 are seen to have less aggressive biology and 
expression of HER-2 receptors. With the ageing popu-
lation, there is an increase in the number of diagnosed 
women with breast cancer aged ≥ 70 years; treatment 
in this characteristic age group should be individualised 
to the tumour specific biological features and patient 
related factors. Elderly breast cancer patients should 
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be given the equal opportunity to be offered treatment 
in the same way as their younger counterparts.
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